New Tests for Determination of CNS-Markers for Neurodegenerative Diseases -- MEDICA - World Forum for Medicine



New Tests for Determination of CNS-Markers for Neurodegenerative Diseases

Mediagnost, founded in 1985, is dedicated to research, development and manufacture of In-vitro-diagnostic test systems and raw materials. Mediagnost has established state-of-the-art labs, and is certified according EN ISO 9001:2000 and EN ISO 13485:2003. All test systems for clinical diagnostics are in compliance with the European Medical Device Directive 98/79/EC and are CE-labeled.

The company operates in several medical and scientific fields. Main focus up to now was endocrinology and infectiology. Mediagnost offers special products for e.g. differential growth diagnostics (Growth Hormone and related Insulin-like Growth Factors and their Binding Proteins), for adipokine research (hormones like Adiponectin or Leptin), or, for determination of Hepatitis A Virus (Infection and the Virus itself).

Recently, Mediagnost started to evaluate new diagnostic strategies for initial diagnosis and diagnostic work-up of central nervous system diseases.

Certain diseases with different pathology are covered by this research and development activity. Current projects are dealing with Multiple Sclerosis (MS), or Parkinson Disease, or Alcohol Addiction.
First success was already achieved by investigating the autoantibody status of MS patients against certain antigen targets (1).

The same approach lead to promising results in case of Parkinson disease and Dementias (2).

Aim of both tests is the pre-symptomatic detection of neurodegenerative diseases to allow early therapeutic intervention. Initial proof of concept studies have shown that Parkinson patients can be differentiated by their autoantibody profile from patients with non-Parkinson neurological diseases.

In case of Alcoholism, the ratio for the commitment of Mediagnost is to provide physicians and researchers a tool for detection of harmful chronic alcohol consumption, and to differentiate it from accepted and tolerable, “normal”, consumption levels. The successful idea here was to measure not the activity, as usual, but the amount of the enzyme Monoamine oxidase B (MAO-B). This turns out MAO-B as a valuable potential new marker for alcoholism (3).

First new test systems are already available:
E100 Anti-Neuro Auto-Antibodies ELISA

Dr. Markus Langkamp, Dr. Lutz Pridzun